HZNP Horizon Pharma plc

21.88
-0.04  -0%
Previous Close 21.92
Open 22.02
Price To Book 4
Market Cap 3667655020
Shares 167,625,915
Volume 1,109,721
Short Ratio
Av. Daily Volume 1,851,382

SEC filingsSee all SEC filings

  1. 8-K - Current report 19512346
  2. 8-K - Current report 19508475
  3. CT ORDER - Confidential treatment order 181237596
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181164787
  5. 8-K - Current report 181164677

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 8, 2016 - primary endpoint not met.
ACTIMMUNE
Friedreich's Ataxia (FA)
Phase 3 data due 1Q 2019.
Teprotumumab
Thyroid Eye Disease (TED)
Phase 2 trial initiation announced September 27, 2018.
Krystexxa with Methotrexate
Gout

Latest News

  1. Do Options Traders Know Something About Horizon Pharma (HZNP) Stock We Don't?
  2. See what the IHS Markit Score report has to say about Horizon Pharma PLC.
  3. Blue Chips Pare Losses; JPMorgan, Goldman Sachs Lead Dow Jones
  4. Horizon Pharma Surged On Earnings But Came Back Down With The Market
  5. IBD 50 Stocks To Watch: Horizon Pharma Setting Up New Buy Point
  6. IBD 50 Growth Stocks To Watch
  7. Big Gains on the Horizon for This Pharma Stock, History Says
  8. Horizon Pharma plc and HemoShear Therapeutics Enter into Exclusive Drug Discovery Collaboration in Gout
  9. Horizon Pharma (HZNP) Up 28% on Business Expansion Strategy
  10. 3 Top Mid-Cap Stocks to Buy Right Now
  11. Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group
  12. S&P 500 Today Down Sharply; This Sign Will Tell A Lot About Current Stock Market
  13. Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Include Newborns
  14. Challenges Facing Health Care Stocks in 2019
  15. Why Horizon Pharma Public Limited Company’s (NASDAQ:HZNP) CEO Pay Matters To You
  16. Horizon Pharma, Inc. -- Moody's affirms Horizon Pharma's B2 CFR; revises outlook to stable from negative
  17. Horizon Pharma plc to Present at the 37th Annual J.P. Morgan Healthcare Conference
  18. Do Hedge Funds Love Horizon Pharma Public Limited Company (HZNP)?

SEC Filings

  1. 8-K - Current report 19512346
  2. 8-K - Current report 19508475
  3. CT ORDER - Confidential treatment order 181237596
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181164787
  5. 8-K - Current report 181164677
  6. 8-K - Current report 181130515
  7. 8-K - Current report 181078702
  8. CT ORDER - Confidential treatment order 181068114
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18999799
  10. 8-K - Current report 18999761